Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study

NCT03364764 is registered in ClinicalTrials.gov with Bing Han as lead sponsor.

NCT NCT03364764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study
Lead sponsor
Bing Han
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2018
Completion date
May 1, 2021
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pure red cell aplasia